Search

Search Constraints

You searched for: Author/Creator Engel, Samuel S.

Search Results

1. A randomised, double‐blind, trial of the safety and efficacy of omarigliptin (a once‐weekly DPP‐4 inhibitor) in subjects with type 2 diabetes and renal impairment. Issue 6 (27th April 2017)

2. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. (3rd October 2017)

4. A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes. Issue 2 (22nd December 2021)

5. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study. Issue 12 (16th August 2018)

6. A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone. (3rd April 2017)

7. A randomized study on the usefulness of an electronic outpatient hypoglycemia risk calculator for clinicians of patients with diabetes in a safety-net institution. (2nd April 2020)

8. A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes. (April 2018)

9. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. (3rd October 2017)